Yi Li

Title: Profile of Yi Li: Innovator in T-Cell Receptor Technology

Introduction

Yi Li, based in Abingdon, GB, is an accomplished inventor renowned for his significant contributions to the field of immunotherapy. With an impressive portfolio comprising 23 patents, his work primarily focuses on engineered T-cell receptors designed to enhance the immune response against HIV.

Latest Patents

Yi Li's latest patents include groundbreaking innovations in T-cell receptor technology, such as "Engineered immune-mobilizing T-cell receptors with enhanced affinity for HIV-1 Gag." This invention pertains to T-cell receptors (TCRs) that specifically bind to the HLA-A*02 restricted peptide SLYNTVATL, originally derived from the HIV Gag gene product, p17. The engineered TCRs showcase non-natural mutations within their variable domains that significantly boost their affinity and specificity, driving a notably potent T-cell response. This technology holds promise for developing soluble immunotherapeutic agents targeting HIV-infected individuals.

Another key patent is "High-stability T-cell receptor and preparation method and application thereof," which introduces a T-cell receptor designed with mutations in its hydrophobic core domain to enhance stability. The patent outlines a method for preparing these TCRs and demonstrates their various applications, further solidifying Yi Li’s status as a leading innovator in this space.

Career Highlights

Throughout his career, Yi Li has made substantial impacts while working at prominent companies, including Immunocore Limited and Adaptimmune Limited. His involvement in these organizations has allowed him to translate innovative ideas into applicable solutions for therapies that aim to combat severe diseases like HIV.

Collaborations

Yi Li has collaborated with notable professionals in his field, including Bent Karsten Jakobsen and Peter Eamon Molloy. These collaborations have contributed to his extensive expertise and the successful development of his patents, fostering advancements in immunotherapy.

Conclusion

Yi Li is a significant figure in the realm of T-cell receptor technology, demonstrating a profound commitment to innovation within the field of immunotherapy. His patents not only showcase his inventive capabilities but also hold potential for transformative impacts in treating diseases, particularly HIV. His work continues to inspire further research and development, paving the way for future advancements in medical treatments.